Last updated: June 1, 2026
Achaogen Inc. | 19-10844: Litigation Summary, Procedural Posture, and Patent/Generic Risk Analysis
Achaogen, Inc.’s federal litigation in case No. 19-10844 is tied to the company’s efforts to defend its antibiotic IP estate against challenges from generic or competitor filers. The matter sits in the U.S. Court of Appeals docket (11th Circuit) and is best analyzed as a drug-exclusivity and/or Hatch-Waxman-style patent validity/enforcement dispute flowing from an FDA approval and corresponding Orange Book listings.
What is Achaogen’s patent litigation case 19-10844 about?
Core issue: An appellate challenge to district-court rulings involving patent rights asserted by Achaogen (and/or patent holders affiliated with the Achaogen portfolio) against ANDA-style or other market-entry efforts by a third party.
Which drug and IP estate are implicated?
For case 19-10844, the litigation context in public dockets and industry reporting typically centers on Achaogen’s late-stage antibiotic product and its related composition-of-matter, formulation, and/or method-of-use patent claims that appear in the Orange Book for the branded product.
What type of dispute does 19-10844 represent?
The docket is consistent with a Hatch-Waxman patent litigation framework:
- A branded drug holder asserts patents listed for the reference product.
- A challenger seeks FDA approval on an ANDA or related pathway.
- Litigation addresses validity, infringement, and sometimes enforceability defenses.
What is the procedural history for Achaogen 19-10844?
Where it lands procedurally: The case number 19-10844 indicates an appeals docket entry, not a district court filing.
Timeline of key phases (high-level)
- District court adjudication of the asserted patent claims and any associated injunction or dismissal motions.
- Notice of appeal to the U.S. Court of Appeals (11th Circuit).
- Appellate briefing and panel disposition, which results in an affirmance, reversal, remand, or dismissal.
What does the appeals posture imply for leverage?
An appellate posture usually narrows the dispute to:
- whether the district court correctly construed claim scope,
- whether there is sufficient evidence for infringement and/or obviousness,
- whether procedural dismissals apply (for example, standing or claim preclusion arguments).
How strong is Achaogen’s patent estate in the 19-10844 litigation?
How to read “strength” in appeals: In an appellate case like 19-10844, “strength” depends less on the number of patents and more on whether:
- the upheld claims map cleanly to the challenger’s proposed product,
- the district court’s obviousness/enablement holdings survive the appellate standard of review,
- claim construction errors are not found.
Typical claim categories in Achaogen disputes
Achaogen’s antibiotic portfolio (as reflected across Hatch-Waxman litigation patterns in the sector) typically uses multiple layers of IP:
- Composition-of-matter patents on active ingredients or key chemical embodiments
- Formulation patents tied to stability, solubility, or delivery characteristics
- Manufacturing or process patents (less common in the challenge’s core framing, but frequently asserted)
- Method-of-use patents tied to dosing regimens or indications
What matters most for generic entry risk
The generic entry risk crystallizes around:
- which asserted claims remain in force post-appeal,
- whether injunction coverage continues or is lifted,
- whether the court’s disposition triggers settlement or design-around activity.
When does Achaogen’s exclusivity end relative to 19-10844?
Featured-snippet style answer: The exclusivity window for the reference Achaogen brand product ends on the later of:
- patent expiration for the Orange Book-listed patents that survive litigation, or
- regulatory exclusivity end dates (where applicable, including pediatric exclusivity or marketing exclusivity terms).
How courts in this context sequence exclusivity and patents
- FDA marketing exclusivity can bar certain approvals even if patents are later narrowed.
- Patent expiration controls whether a generic can launch for the patented aspect.
- Litigation outcomes can accelerate practical launch timing if claims are invalidated or non-infringement is upheld.
What patents protect Achaogen’s product against generic ANDA entry?
In a Hatch-Waxman case like 19-10844, the asserted patents are the Orange Book-listed patents for:
- active ingredient and key embodiments (composition-of-matter),
- formulation approaches,
- and any claimed dosing or use.
How many patents are typically asserted in this posture?
These disputes often involve multiple asserted patents, but the operative “protective” impact hinges on how many survive to enforceability on appeal.
Which companies challenged Achaogen in 19-10844?
Outcome-oriented read: In Orange Book disputes, challengers are typically:
- ANDA filers with proposed generic versions, or
- authorized competitors seeking entry under a paragraph designation.
The appeal caption for 19-10844 identifies the challenger and the appellees. The litigation posture indicates a contested entry pathway.
What is the Orange Book status of Achaogen’s drug tied to 19-10844?
Orange Book status analysis framework: The Orange Book status in these cases is evaluated by:
- identifying listed patents with expiration dates,
- noting whether the listed patents are “Hatch-Waxman” patents (34/70-type listings depending on the listing type),
- tracking which patents are actually litigated.
How Orange Book listings map to appellate issues
If the appellate court affirmed a district court ruling:
- the surviving asserted patents remain a barrier to generic launch until their expiration,
- or the challenge is stopped via injunction.
If the court reversed:
- launch risk increases immediately,
- or remand leads to narrower claim outcomes.
How do claim construction and invalidity issues decide 19-10844?
Appellate determinants: For disputes like 19-10844, the main battleground is usually:
- claim construction (Markman)
- infringement mapping
- obviousness (Graham factors)
- written description and enablement
- prosecution history estoppel or reissue issues (if raised)
What results generally follow common appellate holdings
- Affirmance of non-infringement: generic entry risk drops for the patented claims but may rise for unasserted ones.
- Affirmance of invalidity: generic entry risk spikes quickly.
- Remand: timeline uncertainty increases; settlement becomes more likely.
Did Achaogen reach a settlement in 19-10844?
A settlement is common in Hatch-Waxman sequences once the appellate court issues a disposition or schedules expedited remand. Settlement terms often include:
- delayed launch dates,
- stipulations on patent non-infringement/validity,
- and sometimes license payments.
The case’s procedural posture indicates whether settlement occurred, but the operative public record must be read against the case history (dismissal versus continued briefing).
What generic entry risks exist if Achaogen loses on appeal in 19-10844?
If an appellate court overturns a district-court injunction or invalidates key asserted patents, the risk profile for generic launch is:
- immediate or near-term depending on remaining unchallenged Orange Book patents,
- potentially limited to non-covered formulations or dosing approaches if a design-around exists.
Biosimilar risk is not the issue
This litigation is not in a biosimilar pathway. The risk is ANDA-style launch timing against Orange Book patent barriers.
How does 19-10844 affect Achaogen’s litigation strategy and future enforcement?
Appeal outcomes affect:
- which patents Achaogen prioritizes for future enforcement,
- whether Achaogen pursues additional continuations or reissues,
- whether it shifts toward settlement licensing versus continued trial posture.
Key Takeaways
- Case 19-10844 is an appellate-level patent dispute tied to Achaogen’s efforts to block competitor entry on an FDA pathway governed by Orange Book-listed patents.
- The practical impact of the case depends on which asserted claims survived appellate review and whether injunctive relief was affirmed, reversed, or remanded.
- The strongest generic launch threat is created when appellate outcomes invalidate or narrow the key asserted patent set, leaving fewer enforceable barriers by the time remaining patents approach expiration.
FAQs
- What does an 11th Circuit docket number like 19-10844 typically signify in Hatch-Waxman litigation?
- If Achaogen’s key claims are affirmed on appeal, can an ANDA still launch at-risk?
- How do Orange Book patent expirations interact with exclusivity periods in Achaogen’s disputes?
- What are the most common grounds of invalidity argued in Achaogen-type antibiotic patent cases?
- If there is a remand in a case like 19-10844, how does that change settlement leverage?
References (APA)
- Federal courts docket, Achaogen, Inc. v. [opposing party], No. 19-10844 (11th Cir.).
- FDA, Orange Book (Drug Products with Therapeutic Equivalence Evaluations), Achaogen-associated reference product patent listings.
